FOLR1-targeted Actinium-225-based Alpha-particle Therapy Eliminates Ovarian Cancer.
Publication/Presentation Date
10-27-2025
Abstract
Despite the advancement in therapies, ovarian cancer treatment is challenging due to poor prognosis and high relapse associated with acquired resistance. Targeting overexpression of FOLR1 in ovarian cancers has proven to be an attractive strategy. The recent FDA approval of FOLR1 targeted antibody drug conjugate has shown promising results albeit resistance with repeated use appears inevitable. Emerging targeted alpha-particle therapies, particularly Actinium-225 (
ISSN
2692-8205
Published In/Presented At
Singh, N., Need, E., Berndt, A., Goff, M., Wilson, L., Mourtada, F., Guo, F., Mastren, T., Al-Hilal, T., Sood, A. K., Maity, A., Miller, S. C., Minoshima, S., Goel, S., & Shi, S. (2025). FOLR1-targeted Actinium-225-based Alpha-particle Therapy Eliminates Ovarian Cancer. bioRxiv : the preprint server for biology, 2025.10.27.684721. https://doi.org/10.1101/2025.10.27.684721
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
41279140
Department(s)
Administration and Leadership
Document Type
Article